ArticlePloS one2012
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- MS Fatigue Post High-Efficacy Treatment.European journal of neurology · 2025Pooled it
- Instruments measuring change in cognitive function in multiple sclerosis: A systematic review.Brain and behavior · 2023Pooled it
- Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review.CNS drugs · 2020Pooled it
- Pharmacological treatment for memory disorder in multiple sclerosis.The Cochrane database of systematic reviews · 2013Pooled it
- Computer-assisted rehabilitation of attention in pediatric multiple sclerosis and ADHD patients: a pilot trial.BMC neurology · 2018Trial
- Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting.PloS one · 2013Trial
- Impact of Natalizumab on Productivity and Ability to Work in Patients with Multiple Sclerosis in France: The TITAN Study.Neurology and therapy · 2025Article
- Uncovering heterogeneous cognitive trajectories in relapsing-remitting multiple sclerosis: a longitudinal study.Acta neurologica Belgica · 2025Article
- Insight into motor fatigue mechanisms in natalizumab treated multiple sclerosis patients with wearing off.Scientific reports · 2024Article
- A comparison of natalizumab's effects on SDMT between pediatric-onset and adult-onset multiple sclerosis patients.Frontiers in neurology · 2024Article
- Impact of Disease Modifying Therapy on MS-Related Fatigue: A Narrative Review.Brain sciences · 2023Review
- Comparative effectiveness of natalizumab on cognition in multiple sclerosis: A cohort study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Article
- Article
- Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Multiple sclerosis-related fatigue lacks a unified definition: A narrative review.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2022Review
- Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis.European journal of neurology · 2021Article
- Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Observational
- A Randomized Computer-Assisted Rehabilitation Trial of Attention in Pediatric Multiple Sclerosis: A Post Hoc Analysis.Brain sciences · 2021Article
- Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesNatalizumab reduces the relapse rate and magnetic resonance imaging activity in patients with Relapsing-Remitting Multiple Sclerosis (RRMS). So far the influence of natalizumab on cognitive functions and fatigue in MS remains uncertain. The aim of this prospective, open-label, observational study was to evaluate the possible effects of natalizumab on cognition and fatigue measures in RRMS patients treated for up to two years.
methodsCognitive performances were examined by the Rao's Brief Repeatable Battery (BRB), the Stroop test (ST) and the Cognitive Impairment Index (CII), every 12 months. Patients who failed in at least 3 tests of the BRB and the ST were classified as cognitively impaired (CI). Fatigue Severity Scale (FSS) was administered every 12 months to assess patient's self-reported fatigue. One hundred and 53 patients completed 1 and 2 year-natalizumab treatment, respectively.
resultsAfter 1 year of treatment the percentage of CI patients decreased from 29% (29/100) at baseline to 19% (19/100) (p = 0.031) and the mean baseline values of CII (13.52±6.85) and FSS (4.01±1.63) scores were significantly reduced (10.48±7.12, p<0.0001 and 3.61±1.56, p = 0.008). These significant effects were confirmed in the subgroup of patients treated up to two years.
conclusionsThese results demonstrate that a short-term NTZ treatment may significantly improve cognitive performances and fatigue in RRMS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.